Tempest Therapeutics Inc (TPST)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.64M
Last updated: Nov 17, 2026 at 4:34 PM ET
Tempest Therapeutics Inc (TPST) Statistics
Tempest Therapeutics (TPST) has a market cap of $7.64M and an enterprise value of $12.66M. Its share count is up 280.85% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 65.80% above the market cap, as debt exceeds cash.
| Market Cap | $7.64M |
|---|---|
| Enterprise Value | $12.66M |
| Latest price (Nov 17, 2026) | $0.33 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 96.39% over 52 weeks and trades 50.00% below its 50-day average.
| Beta (1Y) | 1.04 |
|---|---|
| 52-Week Change | -96.39% |
| 1-Month Change | -45.46% |
| 3-Month Change | -69.41% |
| 6-Month Change | -81.61% |
| 5-Year Change | -99.67% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -96.39% |
| Total Return (3Y CAGR) | -80.61% |
| Total Return (5Y CAGR) | -70.28% |
| Max Drawdown (1Y) | -96.51% |
| Max Drawdown (3Y) | -99.54% |
| Sharpe Ratio (1Y) | -2.57 |
| Correlation with SPY (1Y) | 0.11 |
| 50-Day Average | $0.66 |
| 200-Day Average | $1.36 |
| 52-Week Range | $0.34 to $9.25 |
| RSI (14 Days) | 23.5 |
| Average Volume (20 Days) | 224.37K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.34x current liabilities.
| Current Ratio | 0.34x |
|---|---|
| Quick Ratio | 0.34x |
Returns and Efficiency
Return on invested capital is -783.63% over the last 12 months.
| Return on Assets (ROA) | -463.30% |
|---|---|
| Return on Invested Capital (ROIC) | -783.63% |
| Return on Capital Employed (ROCE) | -991.94% |
| ROA (5Y Average) | -85.85% |
Scores
TPST has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$65.00K |
| Operating Income | -$39.87M |
| Pretax Income | -$40.59M |
| Net Income | -$40.59M |
| EBIT | -$40.59M |
| Reported EPS (TTM) | -$1.67 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $897.00K |
|---|---|
| Total Debt | $5.92M |
| Net Debt | $5.03M |
| Net Debt Per Share | $0.30 |
| Working Capital | -$3.06M |
| Shareholder Equity | -$1.83M |
| Total Assets | $8.76M |
| Total Liabilities | $10.59M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$16.00M |
|---|---|
| FCF Per Share | -$0.80 |
| Depreciation and Amortization | $241.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +13.66% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +13.66% |
Dividends and Yields
TPST does not pay a dividend.
| Buyback Yield | -169.59% |
|---|---|
| Shareholder Yield | -169.59% |
Stock Splits
The last split was a 1-for-13 reverse split on Apr 9, 2025.
| Last Split Date | Apr 9, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:13 |
Peer Position
Against 3 similar companies, TPST has the lowest ROIC.
ROICPeer median -72.27%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -99.32%
| ROIC | -783.63% vs -72.27% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -99.32% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TPST
What is TPST's market cap?
Tempest Therapeutics has a market cap of $7.64M. Its enterprise value, which adds debt and subtracts cash, is $12.66M.
How many shares of TPST are outstanding?
Tempest Therapeutics has 16.91M shares outstanding. The count is up 280.85% from a year earlier.
Does TPST pay a dividend?
No. Tempest Therapeutics does not pay a dividend.
How much debt does TPST have?
Tempest Therapeutics has $5.92M of total debt and $897.00K of cash and equivalents, a net debt position of $5.03M.
TPST pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors